Montserrado County Flag
U.S. Health Official Pats Liberians Over Trial Vaccines
MONROVIA, March 31 (LINA) – An official of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has commended Liberian volunteers who participated in the first stage of the clinical trials of two Ebola vaccines candidates.
“We are grateful to the Liberian people who volunteered for this important clinical trial and encouraged by the study results seen with the two investigational Ebola vaccine candidates,” said NIAID Director Anthony S. Fauci, M.D.
“Now we must move forward to adapt and expand the study so that ultimately we can determine whether these experimental vaccines can protect against Ebola virus disease and therefore be used in future Ebola outbreaks,” said Fauci.
Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) trial, according to interim findings from an independent Data and Safety Monitoring Board review.
The PREVAIL trial, which began on February 2, 2015 in Monrovia, is testing the safety and efficacy of the cAd3-EBOZ candidate vaccine co-developed by NIAID scientists and GlaxoSmithKline, and the VSV-ZEBOV candidate vaccine developed by the Public Health Agency of Canada and licensed to NewLink Genetics Corporation and Merck.
The trial is also double-blinded, meaning that neither study subjects nor staff know whether a vaccine or placebo was administered. A randomized, double-blind, placebo-controlled trial is considered the “gold standard” in clinical research, according to a NIAID statement.
NIAID conducts and supports research at NIH, throughout the United States, and worldwide, to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.